BioVersys AG (SWX: BIOV)
Health Care · Pharmaceuticals · CH
CHF25.00
-5.66% today · +4.3% 1Y
BioVersys AG (SWX: BIOV) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $191.51M.
Over the last twelve months the share price has gained 4.3%, trading between 21.20 and 33.90.
Tweenvest scores BioVersys AG across four factors: quality 31/100, value 41/100. Its strongest factor is value.
BIOV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $191.51M
- Revenue (TTM)
- $4.00M
- P/E
- —
- EPS
- -3.89
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- CHF33.90
- 52-week low
- CHF21.20
- Avg volume (3M)
- —
- Shares outstanding
- 5.87M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.75 | +0.19% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.56 | +0.66% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.